24/7 Market News Snapshot 13 October, 2025 – Aclarion, Inc. Common Stock (NASDAQ:ACON)
DENVER, Colo., 13 October, 2025 (www.247marketnews.com) – (NASDAQ:ACON) are discussed in this article.
Aclarion, Inc. has captured significant attention in the financial and healthcare sectors following a notable pre-market trading surge and its participation in the International Society of Pain and Neuroscience (ISPN) Annual Meeting. As of the latest trading session, Aclarion shares are significantly up by 30.01%, reaching $11.177 from the previous closing price of $8.597, supported by a robust trading volume of 2.14 million shares. This pronounced increase reflects strong investor interest and confidence in Aclarion’s innovative advancements and market potential.
At the ISPN Annual Meeting, Aclarion showcased its groundbreaking Nociscan® platform, designed to enhance diagnostic capabilities for chronic low back pain, a condition affecting over 266 million individuals globally. Co-moderated by physician Doug Beall, M.D., the event highlighted the pivotal role of disc chemistry in pain diagnosis, emphasizing a multi-disciplinary approach to spine care. The Nociscan® technology utilizes Magnetic Resonance Spectroscopy (MRS) integrated with proprietary artificial intelligence algorithms, offering healthcare providers valuable insights to differentiate between painful and non-painful discs in the lumbar region. This non-invasive technique enables tailored treatment strategies aimed at improving patient outcomes.
Brent Ness, CEO of Aclarion, expressed enthusiasm regarding the company’s advancements and the opportunity to engage with key thought leaders in the field. He underscored the ongoing commitment to innovation that has characterized Aclarion’s journey thus far. The discussions at the ISPN meeting also underlined the significance of collaborative efforts in advancing diagnostic technologies, with Dr. Beall’s insights into MR spectroscopy’s efficacy adding depth to the conversation. With these initiatives, Aclarion stands poised to enhance its position in pain management and continues to lead efforts in combating chronic low back pain through technological innovation.